Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trillium Therapeutics

Division of Trillium Therapeutics Inc.
www.trilliumtherapeutics.com

Latest From Trillium Therapeutics

Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

ImmunoOncology Deals

Deals In Depth: March 2013

AstraZeneca paid $240 million for rights to Moderna’s RNA therapeutics. Argon Medical acquired Angiotech’s interventional business for $362.5 million. PIPEs accounted for 31% of the $976 million in biopharma financing. FOPOs, on the other hand, dominated the $523 million in device fundraising.

BioPharmaceutical Medical Device

IN VIVO: Deals Shaping The Medical Industry, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Recent Tech Transfer Deals, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on licensing agreements between universities or other research institutions and biopharma, medtech, and diagnostic start-ups.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Transplantation Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Trillium Therapeutics Inc.
  • Senior Management
  • Niclas Stiernholm, PhD, CEO
    Bob Uger, PhD, VP, R&D
    Eric L Sievers, MD, CMO
  • Contact Info
  • Trillium Therapeutics
    Phone: (416) 595-0627
    96 Skyway Ave.
    Toronto, M9W 4Y9
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register